Logo image of ATNM

ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Fundamental Analysis

NYSEARCA:ATNM - NYSE Arca - US00507W2061 - Common Stock - Currency: USD

1.23  +0.06 (+5.13%)

After market: 1.18 -0.05 (-4.07%)

Fundamental Rating

2

ATNM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. The financial health of ATNM is average, but there are quite some concerns on its profitability. ATNM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ATNM has reported negative net income.
In the past year ATNM has reported a negative cash flow from operations.
In the past 5 years ATNM always reported negative net income.
ATNM had negative operating cash flow in 4 of the past 5 years.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M

1.2 Ratios

ATNM has a Return On Assets of -49.83%. This is comparable to the rest of the industry: ATNM outperforms 47.78% of its industry peers.
The Return On Equity of ATNM (-107.08%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -49.83%
ROE -107.08%
ROIC N/A
ROA(3y)-39.89%
ROA(5y)-68.16%
ROE(3y)-72.51%
ROE(5y)-128.35%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

ATNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATNM has more shares outstanding
The number of shares outstanding for ATNM has been increased compared to 5 years ago.
ATNM has a worse debt/assets ratio than last year.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.53, we must say that ATNM is in the distress zone and has some risk of bankruptcy.
ATNM has a Altman-Z score of -6.53. This is in the lower half of the industry: ATNM underperforms 67.50% of its industry peers.
ATNM has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ATNM has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.53
ROIC/WACCN/A
WACC9.56%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 10.25 indicates that ATNM has no problem at all paying its short term obligations.
The Current ratio of ATNM (10.25) is better than 80.64% of its industry peers.
A Quick Ratio of 10.25 indicates that ATNM has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.25, ATNM belongs to the best of the industry, outperforming 80.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.25
Quick Ratio 10.25
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.46%, which is quite impressive.
ATNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.14%.
EPS 1Y (TTM)27.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.49%
Revenue 1Y (TTM)-92.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.36% yearly.
The Revenue is expected to grow by 203.41% on average over the next years. This is a very strong growth
EPS Next Y22.42%
EPS Next 2Y21.86%
EPS Next 3Y11.35%
EPS Next 5Y8.36%
Revenue Next Year5.08%
Revenue Next 2Y1238.81%
Revenue Next 3Y-36.1%
Revenue Next 5Y203.41%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.86%
EPS Next 3Y11.35%

More info and screens

0

5. Dividend

5.1 Amount

ATNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (2/20/2025, 8:04:00 PM)

After market: 1.18 -0.05 (-4.07%)

1.23

+0.06 (+5.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-14 2025-03-14/amc
Inst Owners28.13%
Inst Owner Change-1.44%
Ins Owners2.04%
Ins Owner Change0%
Market Cap38.38M
Analysts81.82
Price Target5.1 (314.63%)
Short Float %6.6%
Short Ratio7.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.03%
Min EPS beat(2)-7.96%
Max EPS beat(2)8.01%
EPS beat(4)3
Avg EPS beat(4)19.97%
Min EPS beat(4)-7.96%
Max EPS beat(4)41.55%
EPS beat(8)5
Avg EPS beat(8)6.59%
EPS beat(12)6
Avg EPS beat(12)-10.07%
EPS beat(16)9
Avg EPS beat(16)-6.5%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.79%
EPS NQ rev (1m)2.22%
EPS NQ rev (3m)23.67%
EPS NY rev (1m)-5.07%
EPS NY rev (3m)-5.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 473.78
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.83%
ROE -107.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.89%
ROA(5y)-68.16%
ROE(3y)-72.51%
ROE(5y)-128.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.36%
Cap/Sales 13.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.25
Quick Ratio 10.25
Altman-Z -6.53
F-Score5
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)32.37%
Cap/Depr(5y)33.78%
Cap/Sales(3y)78.68%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.49%
EPS Next Y22.42%
EPS Next 2Y21.86%
EPS Next 3Y11.35%
EPS Next 5Y8.36%
Revenue 1Y (TTM)-92.14%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year5.08%
Revenue Next 2Y1238.81%
Revenue Next 3Y-36.1%
Revenue Next 5Y203.41%
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.21%
EBIT Next 3Y2.27%
EBIT Next 5Y-3.84%
FCF growth 1Y-415.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-406.16%
OCF growth 3YN/A
OCF growth 5YN/A